The list of acquired mutations with clinical value in AML is growing. Clinical implementation
of this multitude of markers will require integrated approaches and selection of markers to …

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …

Significant progress has been made in the treatment of acute myeloid leukemia (AML).
Steady gains in clinical research and a renaissance of genomics in leukemia have led to …

Acquired chromosome aberrations are present in the marrow of most patients with acute
myeloid leukaemia (AML) at diagnosis. Cytogenetically, AML is a very heterogeneous …

Over the last three decades it has become clear that a significant proportion of cases of
acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent …

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option
for treating acute myeloid leukemia (AML), with no curative option available for patients who …

Introduction Acute myeloid leukemia (AML) is an aggressive malignancy of clonal myeloid
precursor cells. Curative therapy has classically involved the use of intensive induction …

Acute myelocytic leukemia (AML) is a malignant neoplasm of hematopoietic cells
characterized by an abnormal proliferation of myeloid precursor cells, decreased rate of self …

Current treatment of acute myeloid leukemia : Current Opinion in Oncology Current treatment of
acute myeloid leukemia : Current Opinion in Oncology Log in or Register Subscribe to …

Acute myeloid leukemia (AML) is an extremely heterogeneous disease defined by the clonal
growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral …